Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Tae Hoon Roh 2 Articles
Central nervous system
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas
Je Beom Hong, Tae Hoon Roh, Seok-Gu Kang, Se Hoon Kim, Ju Hyung Moon, Eui Hyun Kim, Sung Soo Ahn, Hye Jin Choi, Jaeho Cho, Chang-Ok Suh, Jong Hee Chang
Cancer Res Treat. 2020;52(4):1041-1049.   Published online April 23, 2020
DOI: https://doi.org/10.4143/crt.2020.057
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to evaluate the survival rate and prognostic factors of anaplastic gliomas according to the 2016 World Health Organization classification, including extent of resection (EOR) as measured by contrast-enhanced T1-weighted magnetic resonance imaging (MRI) and the T2-weighted MRI.
Materials and Methods
The records of 113 patients with anaplastic glioma who were newly diagnosed at our institute between 2000 and 2013 were retrospectively reviewed. There were 62 cases (54.9%) of anaplastic astrocytoma, isocitrate dehydrogenase (IDH) wild-type (AAw), 18 cases (16.0%) of anaplastic astrocytoma, IDH-mutant, and 33 cases (29.2%) of anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Results
The median overall survival (OS) was 48.4 months in the whole anaplastic glioma group and 21.5 months in AAw group. In multivariate analysis, age, preoperative Karnofsky Performance Scale score, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, postoperative tumor volume, and EOR measured from the T2 MRI sequence were significant prognostic factors. The EOR cut-off point for OS measured in contrast-enhanced T1-weighted MRI and T2-weighted MRI were 99.96% and 85.64%, respectively.
Conclusions
We found that complete resection of the contrast-enhanced portion (99.96%) and more than 85.64% resection of the non-enhanced portion of the tumor have prognostic impacts on patient survival from anaplastic glioma.

Citations

Citations to this article as recorded by  
  • AQP1 as a novel biomarker to predict prognosis and tumor immunity in glioma patients
    Xiang Gao, Wenqu Jiang, Guofeng Zhu, Zelong Xing, Pengbo Zhu, Zunliang Ke, Qiwei Huang
    Oncologie.2024; 26(1): 117.     CrossRef
  • Decapping enzyme 2 is a novel immune-related biomarker that predicts poor prognosis in glioma
    Yuran Mei, Qiaoli Lv, Zilong Tan, Zhe Zhang, Yulong Ji, Shuhui Chen, Xiaoli Shen
    Biotechnology and Genetic Engineering Reviews.2024; 40(4): 4262.     CrossRef
  • Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis
    Ziming Hou, Jie Hu, Xing Liu, Zeya Yan, Kenan Zhang, Shengyu Fang, Tao Jiang, Yinyan Wang
    Journal of Neuro-Oncology.2023; 164(2): 461.     CrossRef
  • The Impact of Extent of Resection on the Prognosis of Glioblastoma Multiforme: A Systematic Review and Meta-analysis
    Dipak Chaulagain, Volodymyr Smolanka, Andriy Smolanka, Sunil Munakomi
    Open Access Macedonian Journal of Medical Sciences.2022; 10(F): 345.     CrossRef
  • Relative T2-FLAIR signal intensity surrounding residual cavity is associated with survival prognosis in patients with lower-grade gliomas
    Tao Yuan, Zhen Gao, Fei Wang, Jia-Liang Ren, Tianda Wang, Hongbo Zhong, Guodong Gao, Guanmin Quan
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas
    Peng Wang, Jingjing Zhang, Shuai He, Boan Xiao, Xiaobin Peng
    Cancer Cell International.2020;[Epub]     CrossRef
  • 8,290 View
  • 202 Download
  • 14 Web of Science
  • 6 Crossref
Close layer
Association between Levetiracetam Use and Survival in Patients with Glioblastoma: A Nationwide Population-Based Study
Yeonhu Lee, Eunyoung Lee, Tae Hoon Roh, Se-Hyuk Kim
Received April 9, 2024  Accepted September 5, 2024  Published online September 6, 2024  
DOI: https://doi.org/10.4143/crt.2024.355    [Accepted]
AbstractAbstract PDF
Purpose
This study aimed to investigate whether levetiracetam (LEV), the most used antiepileptic drug, influences survival in patients with glioblastoma (GBM), using a national database.
Materials and Methods
This study used data from the Korea Health Insurance Review and Assessment database. Patients diagnosed with GBM between 2007–2018 treated with standard therapy were included. The study population was divided into long-term (≥60 days) and short-term (<30 days) LEV groups. A separate long-term valproic acid (VPA) group (≥60 days) was identified for comparison. Demographics, disease characteristics, and treatment parameters were collected. Kaplan–Meier method and Cox regression were used to compare survival outcomes between the groups.
Results
Overall, 2,971 patients were included, with 1,319 and 1,652 in the short-term and long-term LEV groups, respectively. The median overall survival (OS) for the entire population was 19.15 months post-surgery. Kaplan–Meier analysis revealed a significantly longer median OS in the long-term LEV group versus the short-term LEV group. After adjusting for confounders, Cox proportional hazard analysis revealed an association of long-term LEV use with improved survival, which was also observed in a subgroup analysis of patients without preoperative seizure history. The long-term LEV group demonstrated longer median OS, compared with the long-term VPA group.
Conclusion
Our nationwide population-based study found an association between long-term LEV use and improved survival in patients with GBM, regardless of preoperative seizure history. Prospective studies are needed to validate these findings and investigate the potential impact of LEV on the survival outcomes of patients with GBM.
  • 342 View
  • 38 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP